drugset
drugset / Trial / NCT02147834

Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents

NCT02147834 ↗

Phase 2 Terminated 5 enrolled North Florida Foundation for Research and Education Gilead Sciences · collabUniversity of Florida · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine if ranolazine improves angina symptoms at 4 months compared with placebo among patients who are deferred for receiving a Percutaneous Coronary Intervention (PCI) based on the Fractional Flow Reserve (FFR) measurement.

Timeline

Start
2015-08
Primary completion
2016-03
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ranolazine Small molecule 1000 mg —

Indications

intermediate coronary syndrome